San Francisco, CALIFORNIA4 Active Studies

Endometrial Cancer Clinical Trials in San Francisco, CALIFORNIA

Find 4 actively recruiting endometrial cancer clinical trials in San Francisco, CALIFORNIA. Connect with local research sites and explore new treatment options.

4
Active Trials
4
Sponsors
864
Enrolling

Recruiting Endometrial Cancer Studies in San Francisco

RecruitingSan Francisco, CALIFORNIANCT06989112

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembroliz...

600 participants
AstraZeneca
View Study Details
RecruitingSan Francisco, CALIFORNIANCT04486352

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurren...

148 participants
Alliance Foundation Trials, LLC.
View Study Details
RecruitingSan Francisco, CALIFORNIANCT04814108

A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC)....

76 participants
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
View Study Details
RecruitingSan Francisco, CALIFORNIANCT06463028

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent end...

40 participants
Faeth Therapeutics
View Study Details

About Endometrial Cancer Clinical Trials in San Francisco

Endometrial cancer begins in the lining of the uterus and is the most common gynecologic cancer. It is often detected early due to abnormal bleeding symptoms. Treatment typically involves surgery, with radiation, chemotherapy, or hormone therapy for advanced cases.

There are currently 4 endometrial cancer clinical trials recruiting participants in San Francisco, CALIFORNIA. These studies are seeking a combined 864 participants. Research is being sponsored by AstraZeneca, Alliance Foundation Trials, LLC., K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Endometrial Cancer Clinical Trials in San Francisco — FAQ

Are there endometrial cancer clinical trials in San Francisco?

Yes, there are 4 endometrial cancer clinical trials currently recruiting in San Francisco, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What endometrial cancer treatments are being tested?

The 4 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for endometrial cancer.

Data updated March 2, 2026 from ClinicalTrials.gov